Dr. Lal PathLabs reported a 10.7% increase in revenue for Q2 FY26, reaching ₹731 Cr. EBITDA increased by 10.8%, with a margin of 30.7%. The company also announced an interim dividend of ₹7 per share and approved a bonus issue in the ratio of 1:1. The financial results reflect a strong performance in diagnostic services.
Financial Performance Highlights
Dr Lal PathLabs announced its financial results for the quarter ended September 30, 2025, showcasing substantial growth in revenue and profitability. The company recorded significant increases across key financial metrics:
- Revenue: Increased by 10.7% in Q2 FY26, reaching ₹731 Cr, and by 11.0% for the Half Year (FH26).
- EBITDA: Increased by 10.8% with a margin of 30.7%.
- PAT: Increased by 16.4% with a margin of 20.8%.
Dividend and Bonus Issue
The Board of Directors has approved an interim dividend of ₹7 per share for Q2 FY26. Additionally, a bonus issue has been approved in the ratio of 1:1, where one bonus share will be issued for every one share held on the record date.
Consolidated Financial Overview (₹ Cr)
The following table summarizes the key consolidated financial figures:
Particulars
FY26
FY25
Gr%
FY26
FY25
Gr%
Revenue
731
660
10.7%
1400
1262
11.0%
Material consumed
142
127
271
247
Employee benefit Expenses
132
124
264
241
Fees to collection centres
106
94
198
177
Other Expenses
126
113
250
225
EBITDA
224
202
10.8%
416
372
11.8%
Margins
30.7%
30.7%
29.7%
29.5%
Other Income
25
22
53
42
Depreciation Cost
41
35
75
70
Finance Cost
5
6
9
12
PBT
204
183
11.2%
385
333
15.5%
Margins
27.9%
27.7%
27.5%
26.4%
PAT
152
131
16.4%
286
239
20.0%
Margins
20.8%
19.8%
20.4%
18.9%
EPS
18.1
15.5
16.2%
33.9
28.3
19.9%
About Dr Lal PathLabs Limited
Dr Lal PathLabs is a diagnostic and related healthcare tests and services provider in India. It offers a range of diagnostic and healthcare tests and services. As of March 31, 2025, it has 298 clinical laboratories and a wide network of Patient Service Centers and Pick-up Points.
Source: BSE
